Novartis brings BeiGene's promising checkpoint inhibitor into the fold, but what about highly touted spartalizumab?

Kyle Blankenship

Arriving on the Chinese market among a wave of PD-1 checkpoint inhibitors in late 2019, BeiGene’s tislelizumab has earned laurels for its outstanding data and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis brings BeiGene's promising checkpoint inhibitor into the fold, but what about highly touted spartalizumab?

Kyle Blankenship

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

Kyle Blankenship

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Novartis brings BeiGene's promising checkpoint inhibitor into the fold, but what about highly touted spartalizumab?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial